EFM
AVBP icon

E Fund Management’s ArriVent BioPharma AVBP Stock Holding History

E Fund Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17M Buy
+93,953
New +$2.12M 0.06% 144

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

E Fund Management's AVBP Position: Q1 2026 in Review

E Fund Management opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 93,953 shares worth $2.17M. The stake represents 0.06% of the portfolio and ranks #144 among its holdings.

139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • E Fund Management held 93,953 shares of ArriVent BioPharma worth $2.17M as of Q1 2026.
  • ArriVent BioPharma was a new E Fund Management position in Q1 2026.
  • ArriVent BioPharma made up 0.06% of E Fund Management's portfolio in Q1 2026, its #144 holding.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.